Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Kalamazoo, Michigan Clinical Trials

A listing of Kalamazoo, Michigan clinical trials actively recruiting patient volunteers.

RESULTS

Found (120) clinical trials

Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia

In the study, patients will receive risperidone (4-6 mg/day), or, if recently failed on risperidone, olanzapine (15-20mg/day). Later during the study, patients will be randomized to either receive Lu AF35700 (10 mg/day), or continue their treatment with risperidone or olanzapine.

Phase

92.94 miles

Learn More »

S0820 Adenoma and Second Primary Prevention Trial

The purpose of this study is to assess whether eflornithine 500 mg or sulindac 150 mg are effective in reducing the 3-year event rate of high risk adenoma or second primary colorectal cancer in Stage 0, I II and III colon cancer patients. The primary hypothesis will test the main ...

Phase

2.95 miles

Learn More »

Pentostatin Cyclophosphamide and Rituximab Followed By Lenalidomide in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

OBJECTIVES: Primary - Determine the objective response rate (complete remission, partial remission [PR], or nodular PR) in patients with relapsed or refractory B-cell chronic lymphocytic leukemia (CLL) treated with pentostatin, cyclophosphamide, and rituximab (PCR) followed by lenalidomide. - Determine the presence of minimal residual disease in patients treated with this ...

Phase

2.95 miles

Learn More »

Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

OUTLINE: This is a 2-part, multicenter, randomized study. Patients are stratified according to gender, weight loss 6 months prior to study entry ( 5% of body weight vs > 5% of body weight), ECOG performance status (0 vs 1 vs 2), radiotherapy technique (intensity-modulated radiotherapy vs 3-dimensional conformal radiotherapy), radiotherapy ...

Phase

2.95 miles

Learn More »

Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma Acral Melanoma or Vulvovaginal Melanoma That Cannot Be Removed By Surgery

OBJECTIVES: Primary - To estimate the objective tumor response rate in patients with KIT-positive, unresectable, locally advanced or metastatic acral or mucosal melanoma treated with dasatinib monotherapy. Secondary - To estimate the response duration in patients treated with this drug. - To estimate the progression-free survival of patients treated with ...

Phase

2.95 miles

Learn More »

Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II III or IV Ovarian Fallopian Tube or Primary Peritoneal Cancer

PRIMARY OBJECTIVES: I. To determine if women who are disease-free after successfully completing primary and potential consolidation/maintenance, therapy for stage II-IV ovarian, fallopian tube or primary peritoneal cancer and who are randomized to a healthy lifestyle intervention, will have significantly increased progression-free survival compared to similar women who are randomized ...

Phase

2.95 miles

Learn More »

Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer

PRIMARY OBJECTIVES: I. To assess whether pelvic radiation therapy with concurrent cisplatin is more promising with respect to progression-free survival than pelvic radiation therapy alone in the treatment of recurrent uterine carcinoma limited to the pelvis and vagina. SECONDARY OBJECTIVES: I. To capture the sites of recurrence subsequent to treatment ...

Phase

2.95 miles

Learn More »

BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

OBJECTIVES: Primary - To determine the safety of BLP25 liposome vaccine and bevacizumab after definitive chemoradiotherapy and consolidation chemotherapy in patients with newly diagnosed, unresectable stage IIIA or IIIB nonsquamous cell non-small cell lung cancer. Secondary - To evaluate the overall survival and progression-free in patients treated with this regimen. ...

Phase

2.95 miles

Learn More »

Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer Fallopian Tube Cancer or Primary Peritoneal Cancer

PRIMARY OBJECTIVES: I. To estimate the antitumor activity of elesclomol (elesclomol sodium) and paclitaxel in patients with persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer primarily through the frequency of objective tumor responses. II. To determine the nature and degree of toxicity of elesclomol and paclitaxel in these ...

Phase

2.95 miles

Learn More »

Cetuximab Cisplatin Fluorouracil and Radiation Therapy in Treating Patients With Stage I Stage II or Stage III Anal Cancer

OBJECTIVES: Primary - Determine whether the addition of cetuximab to combined modality therapy (CMT) comprising cisplatin, fluorouracil, and radiotherapy reduces the local failure rate by ≥ 50% at 3 years (compared with historical data) in immunocompetent patients with stage I-IIIB invasive anal carcinoma. Secondary - Determine objective response rate (complete ...

Phase

2.95 miles

Learn More »